Absence of merger signals or regulatory filings underpins the 98.4% market-implied odds against a Merck-Moderna acquisition announcement this year. The companies maintain a long-standing equal-profit collaboration on mRNA-4157/V940, recently reinforced by positive Phase 3 melanoma data showing meaningful risk reductions, which supports continued joint development rather than a full takeover. Moderna’s cost-cutting and low valuation have sparked occasional speculation, yet Merck has pursued separate deals, including the $11.3 billion Bio-Techne acquisition. With no disclosed talks or strategic shifts evident through mid-August 2026, trader consensus reflects the established partnership structure. Tail risks remain limited to unforeseen board-level decisions or major competitive pressures that could prompt a sudden change in control.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated2% chance
NEW
NEW
Dec 31, 2026
2% chance
NEW
NEW
Dec 31, 2026
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Absence of merger signals or regulatory filings underpins the 98.4% market-implied odds against a Merck-Moderna acquisition announcement this year. The companies maintain a long-standing equal-profit collaboration on mRNA-4157/V940, recently reinforced by positive Phase 3 melanoma data showing meaningful risk reductions, which supports continued joint development rather than a full takeover. Moderna’s cost-cutting and low valuation have sparked occasional speculation, yet Merck has pursued separate deals, including the $11.3 billion Bio-Techne acquisition. With no disclosed talks or strategic shifts evident through mid-August 2026, trader consensus reflects the established partnership structure. Tail risks remain limited to unforeseen board-level decisions or major competitive pressures that could prompt a sudden change in control.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Market Opened: Aug 19, 2026, 3:58 PM ET
Volume
$411End Date
Dec 31, 2026Market Opened
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Absence of merger signals or regulatory filings underpins the 98.4% market-implied odds against a Merck-Moderna acquisition announcement this year. The companies maintain a long-standing equal-profit collaboration on mRNA-4157/V940, recently reinforced by positive Phase 3 melanoma data showing meaningful risk reductions, which supports continued joint development rather than a full takeover. Moderna’s cost-cutting and low valuation have sparked occasional speculation, yet Merck has pursued separate deals, including the $11.3 billion Bio-Techne acquisition. With no disclosed talks or strategic shifts evident through mid-August 2026, trader consensus reflects the established partnership structure. Tail risks remain limited to unforeseen board-level decisions or major competitive pressures that could prompt a sudden change in control.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Volume
$411End Date
Dec 31, 2026Market Opened
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...Absence of merger signals or regulatory filings underpins the 98.4% market-implied odds against a Merck-Moderna acquisition announcement this year. The companies maintain a long-standing equal-profit collaboration on mRNA-4157/V940, recently reinforced by positive Phase 3 melanoma data showing meaningful risk reductions, which supports continued joint development rather than a full takeover. Moderna’s cost-cutting and low valuation have sparked occasional speculation, yet Merck has pursued separate deals, including the $11.3 billion Bio-Techne acquisition. With no disclosed talks or strategic shifts evident through mid-August 2026, trader consensus reflects the established partnership structure. Tail risks remain limited to unforeseen board-level decisions or major competitive pressures that could prompt a sudden change in control.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions